Ipamorelin: What It Is and What the Science Supports

Ipamorelin is a synthetic peptide that prompts your pituitary to release its own growth hormone, and it is best known for doing so selectively, with relatively little effect on cortisol, prolactin, or appetite. That selectivity is why it is a community favorite. What it is not is FDA-approved: human evidence is limited, the FDA's advisory committee voted against it for compounding in late 2024, and it is banned in sport at all times.

This article explains what ipamorelin is, how it works, what the (thin) science actually supports, its side-effect profile, and why any use belongs with a licensed provider. Nothing here is a dosing guide or a recommendation to use it.

What ipamorelin is

Ipamorelin is a synthetic pentapeptide (a five-amino-acid chain) that acts as a ghrelin mimetic. Ghrelin is the hormone best known for stimulating hunger, but it also acts on the pituitary to trigger growth-hormone (GH) release. Ipamorelin binds the ghrelin receptor (GHSR) and prompts that GH release, then GH drives production of IGF-1 (insulin-like growth factor 1), the downstream messenger for many of GH's effects.

Like CJC-1295 and sermorelin, ipamorelin is a secretagogue, something that prompts your body to secrete its own GH, not a hormone you inject directly. Our growth hormone peptides explained piece lays out how these classes relate.

The selectivity that defines it

Ipamorelin belongs to the same broad family as the older secretagogues GHRP-2 and GHRP-6, but its defining feature is selectivity. Those older peptides reliably raise GH but also spike cortisol (a stress hormone), prolactin, and appetite, which are unwanted effects for most goals. Ipamorelin is considered the most selective GH secretagogue because it stimulates GH with minimal effect on cortisol, prolactin, or ACTH, and notably without the strong hunger surge of GHRP-6.

That cleaner profile is the entire basis of ipamorelin's popularity. It is a real mechanistic advantage. But it is important to be precise about what it does and does not mean: "more selective, with fewer off-target hormone effects" is not the same as "proven safe over years." Selectivity reduces certain predictable side effects; it does not retroactively supply the long-term human safety data that does not exist.

What the evidence actually shows

The honest state of the science is thin. The bulk of the data on ipamorelin is preclinical, meaning animal studies, which show GH and IGF-1 elevation, some effects on bone density, and limited body-composition effects. Human data is extremely sparse: a handful of small clinical studies and no published Phase III trials. It has been used in some compounding-pharmacy protocols without substantial randomized-trial support.

So the accurate framing is: ipamorelin's mechanism is well characterized, its short-term hormonal effect is plausible and partly demonstrated, and the popular claims about meaningful muscle gain, fat loss, and recomposition are largely extrapolation. "Raises GH" is supported; "transforms your physique safely" is not established. For a clear-eyed look at the recomposition question across this whole class, see GH peptides for body recomposition.

Ipamorelin versus the older GHRPs

To appreciate ipamorelin, it helps to know what came before it. GHRP-2 and GHRP-6 are older ghrelin-receptor agonists that reliably raise GH, but they bring baggage: GHRP-6 in particular produces a strong appetite surge (it is a potent ghrelin mimic in that respect), and both can spike cortisol and prolactin. For most users chasing GH effects, those off-target actions are unwanted, increased hunger, stress-hormone elevation, and the downstream issues prolactin can cause.

Ipamorelin was developed to keep the GH-releasing action while shedding most of that baggage. It is the cleanest signal in the GHRP family: GH up, with comparatively little disturbance to cortisol, prolactin, or appetite. When people call ipamorelin "the gentle one," this is what they mean. The distinction is real and is the entire reason ipamorelin displaced the older peptides in popularity. It is also a reminder that "selective" is a comparative term, it means cleaner than GHRP-6, not proven harmless.

Regulatory status

Ipamorelin is not FDA-approved for any indication. Like CJC-1295, its compounding situation is on the unfavorable end: the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against ipamorelin at both October and December 2024 meetings, meaning it does not currently have a clear path to legal 503A compounding through licensed pharmacies. In practice it circulates as a research chemical.

It is also banned in sport. The WADA 2026 Prohibited List prohibits ipamorelin as a GH secretagogue under category S2, banned at all times, in and out of competition. For a tested athlete, that is disqualifying regardless of dose.

Because it is sold through unregulated vendors, purity, sterility, and endotoxin contamination can vary between sources and between batches. That sourcing risk is often the most concrete day-to-day hazard, ahead of the peptide's own pharmacology.

Safety considerations

Ipamorelin's selectivity genuinely reduces some side effects, but the GH-axis class concerns still apply:

• Fluid retention and carpal-tunnel-like symptoms (numbness, tingling) can occur with GH elevation.
• Glucose effects are relevant for anyone with prediabetes or diabetes.
• IGF-1 and cancer concern. Raising IGF-1 could, in theory, stimulate growth of a pre-existing malignancy. This is a class-wide concern for GH-axis agents and a key reason providers screen before considering any of them.
• Sourcing risk. Gray-market product of unverified quality is a real hazard.

The reputation for being "well tolerated" is reasonable for short-term, selective hormonal effects. It is not a substitute for the long-term safety data that has never been collected.

Why it is paired with CJC-1295

Ipamorelin is rarely run alone. It is most often paired with CJC-1295, a GHRH analog. The logic is that the two act on different receptors, ipamorelin on the ghrelin receptor and CJC-1295 on the GHRH receptor, so combining them may produce a larger, synergistic GH pulse than either alone. This is a mechanistic rationale, not a proven protocol: there are no published combined human trials, so the pairing remains community practice. Our dedicated CJC-1295 and ipamorelin stack article covers the pairing, and the CJC-1295 guide covers its partner in depth.

If you are weighing ipamorelin against the oral GH secretagogue MK-677, our ipamorelin vs MK-677 comparison lays out the tradeoffs, including that MK-677 has more human data but a heavier side-effect profile.

Common reported uses (and the honest caveat)

The goals people pursue with ipamorelin are worth naming so they can be measured against the evidence. It is discussed for body recomposition, improved sleep and recovery, lean-mass support, anti-aging, and general GH "optimization" in middle-aged adults with age-related GH decline. All of these are off-label and unvalidated by outcome trials for ipamorelin specifically.

The pattern here is identical to the rest of this class: the mechanism makes the goals plausible, and plausibility is doing most of the marketing's work. Raising GH could, in principle, support recovery or nudge body composition, but "could in principle" is not "shown in a controlled human trial." Ipamorelin's human evidence does not establish any of these real-world outcomes, and most enthusiasm traces back to mechanism plus anecdote. Reading the topic responsibly means holding that line.

A note on cycling

Because ipamorelin works by repeatedly prompting the GH axis, downregulation, the concern that constant stimulation may blunt the response, is part of why off-cycles come up so often with GH secretagogues. The rationale is plausible but largely unproven in humans, and there is no clinically established cycle length. Our peptide cycling piece covers why those schedules are conventions rather than rules.

What to ask a provider

Given the thin evidence and the screening concern, any consideration of ipamorelin should run through a licensed clinician. Useful questions:

• What screening, including malignancy history, should happen before considering a GH-axis compound?
• Given there are no Phase III trials, what am I actually signing up for, and what would tell us it is working?
• What is the current FDA compounding status and WADA status, and does either rule me out?
• If I am running it with CJC-1295, how should the combined schedule and product quality be handled?

Where Myo fits

If a provider directs an ipamorelin protocol, the practical challenge is keeping a research-peptide routine organized and honest. Myo logs each injection, site, and reconstituted vial in one place, and the reconstitution calculator handles the concentration math so your log reflects the actual dose administered. Reminders keep the prescribed cadence on track, which matters even more when ipamorelin is paired with a different-acting partner.

The more important role, though, is reality-checking. The headline claims for ipamorelin are about body composition, and body composition is exactly where wishful thinking thrives. Myo pairs your injection log with fat-versus-lean body-composition trends, so you can see whether anything is actually changing beyond placebo, and it sits alongside the proven drivers: protein and resistance training. Our resistance training to keep muscle guide covers the mechanical-load signal that does the real work, the thing no secretagogue replaces.

The bottom line: ipamorelin is the selective GH secretagogue, and that selectivity is a genuine, if narrow, advantage. But it is not FDA-approved, has no clear compounding path as of late 2024, is banned in sport, and rests on mostly preclinical evidence with no long-term human safety data. Any use belongs with a provider, and the proven levers for body change still live in the gym and on your plate.

References

• FDA. Pharmacy Compounding Advisory Committee Briefing Document. https://www.fda.gov/media/183819/download
• Lexology. FDA 503A Peptide Update (CJC-1295 and ipamorelin PCAC votes). https://www.lexology.com/library/detail.aspx?g=2e55b76a-3173-4e04-beda-bf021202f18d
• WADA. 2026 Prohibited List. https://www.wada-ama.org/en/prohibited-list
• OPSS. Performance-Enhancing Substance: GH Secretagogues. https://www.opss.org/article/performance-enhancing-substance-mk-677-ibutamoren